LPL and metabolic syndrome: The lack of inhibitory activity on LpL and stimulatory activity on hepatic VLDL secretion (26), confirmed once again in the present study, are key to this variant’s favorable lipid profile, positioning it as a promising therapeutic tool for metabolic syndrome.